Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK alli agreement

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline announces Feb. 20 it has acquired from Roche exclusive rights to weight-loss drug orlistat (alli) for OTC use in markets outside the U.S. excluding Japan. Roche retains marketing rights for the orlistat product Xenical for Rx use. GSK says in a release it anticipates filing orlistat for OTC approval in Europe and other key international markets by the end of 2007. FDA approved alli for OTC use Feb. 7 and GSK plans to launch alli by this summer (1"The Tan Sheet," Feb. 12, 2007, p. 8)...
Advertisement

Related Content

Alli Approved OTC For Weight Loss With “Goal Oriented” Indication
Alli Approved OTC For Weight Loss With “Goal Oriented” Indication

Topics

Advertisement
UsernamePublicRestriction

Register

PS100251

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel